CRIS Current Research Information System

DALL'OLIO, FILIPPO GUSTAVO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.063
NA - Nord America 1.893
EU - Europa 1.588
AF - Africa 161
SA - Sud America 104
OC - Oceania 5
Totale 5.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.851
VN - Vietnam 696
IT - Italia 572
SG - Singapore 551
CN - Cina 432
DE - Germania 188
SE - Svezia 178
GB - Regno Unito 166
HK - Hong Kong 116
NL - Olanda 100
IN - India 91
BR - Brasile 81
FR - Francia 80
IE - Irlanda 56
RU - Federazione Russa 54
KR - Corea 48
FI - Finlandia 45
CH - Svizzera 43
TG - Togo 43
ZA - Sudafrica 32
SC - Seychelles 29
CI - Costa d'Avorio 27
AT - Austria 22
JP - Giappone 22
JO - Giordania 21
CA - Canada 20
BG - Bulgaria 17
NG - Nigeria 16
UA - Ucraina 13
ES - Italia 12
PL - Polonia 12
MX - Messico 11
TH - Thailandia 11
BE - Belgio 9
EE - Estonia 9
IQ - Iraq 9
PH - Filippine 9
TR - Turchia 9
BD - Bangladesh 8
ID - Indonesia 8
PK - Pakistan 8
AR - Argentina 7
EC - Ecuador 6
EG - Egitto 6
TW - Taiwan 6
NI - Nicaragua 5
CO - Colombia 4
AU - Australia 3
OM - Oman 3
PY - Paraguay 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
IR - Iran 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
SA - Arabia Saudita 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KI - Kiribati 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SV - El Salvador 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 5.814
Salva come PNG Salva come JPEG
Città #
Singapore 392
Ashburn 233
Chandler 184
Dong Ket 140
Fairfield 138
Southend 135
Ho Chi Minh City 121
Hanoi 117
San Jose 111
Hong Kong 103
Hefei 99
Santa Clara 99
Bologna 92
Seattle 76
Woodbridge 67
Houston 63
Beijing 62
Wilmington 57
Dublin 56
Princeton 51
Rome 51
Dallas 50
Milan 44
Lomé 43
Cambridge 41
Seoul 38
Boardman 36
Los Angeles 36
Bern 35
Helsinki 35
Lauterbourg 34
New York 30
Abidjan 27
Council Bluffs 24
Turin 22
Amman 21
Ann Arbor 19
Da Nang 19
Frankfurt am Main 19
Munich 18
Buffalo 17
Abeokuta 16
Berlin 16
Bremen 16
Sofia 16
Tokyo 16
Haiphong 15
Johannesburg 15
Westminster 15
Florence 14
Vienna 14
Redondo Beach 13
San Diego 13
Des Moines 12
Redmond 12
Montreal 11
Nanjing 11
Nuremberg 11
Ravenna 11
São Paulo 11
Can Tho 10
Bengaluru 9
Jinan 9
Brussels 8
Chicago 8
Guangzhou 8
Turku 8
Falkenstein 7
Manchester 7
Moncalieri 7
Orem 7
Shenyang 7
Stockholm 7
Warsaw 7
Amsterdam 6
Biên Hòa 6
Bắc Giang 6
Changsha 6
Hải Dương 6
Phoenix 6
Redwood City 6
Rio de Janeiro 6
Torino 6
Visakhapatnam 6
Boston 5
Brescia 5
Brooklyn 5
Bühl 5
London 5
Managua 5
Mexico City 5
Olalla 5
Padova 5
Paris 5
Phủ Lý 5
Pune 5
Quận Bình Thạnh 5
Salt Lake City 5
Shanghai 5
Bari 4
Totale 3.561
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 451
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 276
The 'surprise' question in advanced cancer patients: A prospective study among general practitioners. 275
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 270
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 264
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 259
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 248
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 222
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 217
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 200
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 194
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer 180
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 175
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 157
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role? 154
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study 153
Clinical and demographic factors associated to the place of death in advanced cancer patients assisted at home in Italy 146
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 145
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non–Small Cell Lung Adenocarcinoma 140
Expected and non-expected immune-related adverse events detectable by CT 139
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 136
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 133
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. 133
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 131
Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series 127
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 124
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 123
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 118
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect 115
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates 92
Role of PD-L1 assessment in advanced NSCLC: does it still matter? 80
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 65
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 52
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 36
Totale 5.937
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.177
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.177
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021274 0 0 0 0 0 0 0 0 0 27 10 237
2021/2022591 45 13 24 33 54 18 21 57 38 44 164 80
2022/2023839 60 148 53 99 65 63 26 53 127 18 57 70
2023/2024289 35 35 15 30 21 51 4 26 14 13 21 24
2024/20251.002 70 113 73 54 127 42 54 69 42 108 73 177
2025/20262.183 257 272 177 146 224 137 186 99 503 182 0 0
Totale 5.937